Figure 4 | Scientific Reports

Figure 4

From: Real-time metabolic profiling of oesophageal tumours reveals an altered metabolic phenotype to different oxygen tensions and to treatment with Pyrazinib

Figure 4

Pyrazinib (P3) significantly inhibits OCR and ECAR in OAC patient biopsies cultured under hypoxia (0.5% O2). (A) Percentage change from baseline OCR metabolic rate under hypoxia (0.5% O2) to OCR following treatment with 0.1% DMSO control, 10 µM Pyrazinib (P3) or 6 µM Oligomycin under 0.5% O2, (n = 6). (B) Percentage change from baseline of ECAR metabolic rate under hypoxia to ECAR following treatment with 0.1% DMSO control, 10 µM Pyrazinib (P3) or 6 µM Oligomycin under 0.5% O2, (n = 6). Wilcoxon signed rank t-test,*p < 0.05. Data expressed as mean + SEM.

Back to article page